Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03276832 · ClinicalTrials.gov registry record · Early Phase 1
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT03276832: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT03276832 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 7 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03276832, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This pilot early phase I trial studies the side effects and how well imiquimod and pembrolizumab work in treating patients with stage IIIB-IV melanoma. Imiquimod may stimulate the immune system. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving imiquimod and pembrolizumab may work better at treating melanoma.
Primary Outcome
Defined as the time from response to disease progression.
Interventions
- BIOLOGICAL Pembrolizumab
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy
- PROCEDURE Positron Emission Tomography
- DRUG Imiquimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2019-10-15 |
| Phase | Early Phase 1 |
What the finished NCT03276832 record still lists
NCT03276832 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03276832 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03276832 about?
NCT03276832 is a clinical study titled "Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma". This pilot early phase I trial studies the side effects and how well imiquimod and pembrolizumab work in treating patients with stage IIIB-IV melanoma. Imiquimod may stimulate the immune system. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack...
What is the current status of trial NCT03276832?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2017-12-20. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT03276832?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Computed Tomography (PROCEDURE), Biopsy (PROCEDURE), Positron Emission Tomography (PROCEDURE), Imiquimod (DRUG).
Who is sponsoring clinical trial NCT03276832?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03276832's enrollment target sits among peer trials
7 1826th of 2000 higher than 156 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI